Story
Nvidia, Microsoft, and Tech Giants Urge US Lawmakers to Back Open-Source AI

Summary
A coalition of major technology firms, including Nvidia, Microsoft, and Meta, has publicly advocated against restrictive regulations on open-source AI models, warning lawmakers that such rules could stifle innovation and competition.
A coalition of technology heavyweights including Nvidia (NVDA), Microsoft (MSFT), and Meta Platforms (META) is publicly urging U.S. lawmakers to support the development of open-source artificial intelligence. In a letter published Friday, the group argued against imposing premature or sweeping restrictions on the technology, which they say is critical for competition and innovation.
A Public Push for Open Models
In a letter posted on the social media platform X, Nvidia CEO Jensen Huang and leaders from two dozen other firms, including IBM (IBM), cautioned that lawmakers should avoid "premature restrictions on open models that stifle competition or drive innovation overseas." The statement, first reported by Reuters, represents a significant public stance in the escalating debate over how to regulate the powerful technology.
The letter wades into a central conflict within the AI industry: the battle between open-source models, which are publicly accessible, and closed-source models, which are proprietary systems controlled by companies like OpenAI and Anthropic. The signatories argue that an open approach is essential for security and progress.
The Business Case for Open-Source
The push from industry leaders is rooted in both strategic and economic concerns. Corporate executives have grown wary of the high costs associated with using closed-source models. The CEOs of Microsoft and defense contractor Palantir (PLTR) have previously argued that allowing customers to run open-source models in their own data centers is a key strategy for controlling AI-related expenses.
AdBeyond costs, businesses have also expressed frustration with the usage restrictions built into proprietary models. The letter highlighted the security benefits of open systems, stating, "Open weight models, on the other hand, allow a broad community of researchers and developers to examine their behavior, identify vulnerabilities, develop safeguards, and improve them over time."
Navigating a Complex Regulatory Landscape
The companies' appeal comes as U.S. lawmakers consider new regulations for artificial intelligence. According to the Reuters report, recent proposals include legislation that would mandate a "kill switch" for AI models, prompted by concerns over a rogue AI cyberattack. The administration is also reportedly weighing sanctions on Chinese open-source AI developers over allegations of technology theft.
The letter acknowledged these security concerns but advocated for a more targeted approach. "Relying solely on closed models is not inherently safe: they can be breached, misused, or fail in ways that outsiders cannot detect," the letter stated, arguing that risks like tech theft should be addressed "through targeted legal and commercial frameworks rather than sweeping restrictions."
Read next
More on Stocks
Oura IPO Sees Demand Outstrip Supply by Four Times, Report Says
The health and fitness technology company's initial public offering is attracting significant investor interest, with orders reportedly reaching four times the shares available as it seeks to raise up to $2.2 billion.

Insurance Firm Fidelis Partnership Files for US Initial Public Offering
Insurance firm TFP Group, which operates as the Fidelis Partnership, has filed for an initial public offering in the U.S., setting the stage for a public listing amid a challenging market for new issues.

S&P Cuts Cable One's Credit Rating to 'B+' on Fierce Broadband Competition
S&P Global Ratings has lowered Cable One's issuer credit rating, citing intense pressure from fiber and fixed wireless rivals that is eroding the company's profitability and market share.

Mirum Pharma Gains as Investors Await FDA Ruling on Rare Disease Drug
Shares of Mirum Pharmaceuticals rose in Monday trading as the company approaches a key regulatory decision from the U.S. Food and Drug Administration for its drug candidate, zilurgisertib, which treats an ultra-rare bone disease.